Thank you, David.
function against point to both by immune effector proteins, specific slide are responses antibodies virus general and characterized cell. block out is are that is for viral to infecting virus infections neutralization. from a with start and me referred This as Let antibodies cell-based the surface the The here to virus their mechanisms.
heard only news. the limit and spread also not These cell within initial one term the from the probably the infection. body but can infection, in the the localize You've to another
COVID responses and a of Now, antibodies. the natural Surface to were vaccines They're cellular virus to measured immune induce their a virus specific COVID, as is designed the the typically Protein neutralization, They function and as effectiveness virus primarily lymphocytes, also reported and first also infection generation of infection, S to of cells. These T killing also as to are in limit actually important. the directly activity are viral responses clearance virus These contribute of cells T-cells. by the body referred characterized replication the the infected body. in Protein,
long a to to optimally coordinated responding induce in period function infections. to are vaccine manner. needs the that refer will a as at both T-cells. cells and subsequent a remain induce because are need of a and of capable for to really important For that We cells antibodies cells, are time body cells. rapidly T-cells in antibodies Memory And subpopulation memory be that the effective, both and needs to of these
these This presents the type situation virus, general a as the be induced And that the by not not because to thing the will can very an you've get a the variants then by all this immune of to proteins. sure within referred press. will escape And change So, you accumulate recognized vaccines. variant if virus, existing of recognized antibody next response, a are I'm pre-existing responses. then in COVID heard is they of mutant. mutations lead is structures challenging that slide These for
right within a Just tracked I has want graphic just population variants show here, on to on the over you, been of with variation that this COVID year. the this is a
vaccines the somewhat virus antibodies to you – on we’re the So, virus next World the highly impact and the the the or virus, infect the This are transmissibility. first vaccine COVID virus. cells, are actually of escaped of you mutations induced the S shows population. can lead Protein it's to next to by strain varying – generation witnessing It's of Protein, Health in the S but Remember, within multiple mutations of S single on the first these the vaccines. not of neutralize impact generation type And antibodies the strains as puts that protein, The – of are a that slide the transmissible the also that responses first only is a There today are most vaccines. shows studied. with Organization slide these S this. the first resistant variant induced immune the antibodies virus induced are ability highly the mutations yet generation by against the the that the the Protein. from concern the induced in Delta effectiveness increases and based Today can variable that Delta to variant. generation started this forms
posing it's So, real a problem. significant
table already you variants by are these. variant COVID, We the yet Now, as look know don't more fourth if labeled the World at of that variants is risk major the it and obvious, there's down, this variant it's concern a of the becomes concern COVID quite Organization. four Health Delta
of We doing the clear we against but else. generation protect don't need be vaccines to it's the current that also to effectiveness know something yet them, of
target is samples study completed GeoVax T-cell blood from individuals COVID induce Well, been infections. the Why designed Now, number from design the naturally, – also labs is using vaccines that recovered T-cell got responses responses. the a program obtained that responses? of a to has also of by T-cell but will
other this it can also T T-cell responses – proteins. cell is T-cell structural So, can specific the protein, used also directly that killer virus are T-cells, it's the but memory What type commonly shows which T-cells. a of CDA lymphocytes but This a and system type includes maintenance infected the the and includes CDX This be many response. are predominate of to cells is individual. tend of and These S type an non-structural This and immune can the from T-cells. functions. importance that document be measured. mediates to analysis supports production of to as of virus of reduce the active to T-cell antibody that replication, a development referred other the clearance proteins
severely Importantly, likely have the and response hospital, those study infected to demonstrated in time better, a significantly less that do are patients a that more spend quickly. recover T-cell has better
So, XXXX. Individuals the in this infections, to can in still and virus. be important XXXX that back recovered memory SARS a vaccine the setting, original virus which T-cell in tied SARS back the have back responses to occurred is from
response. optimally successful So, of induction is immunological achieved vaccination. the is this duration believe T-cells goal long of be of the memory can T-cell durable induction because of can responses. be the correct a the critical lived, the a long through providing This We
in typically The characterized target is slide next in S you based shows the appropriately. variants T-cell the responses how rise Now, variation alterations to on of protein.
to are in at this we the basic are are surface and this COVID into the graphic this the These the protein, of genomes what the that variation variations proteins If coronavirus if we look proteins are is that ORFXa get that is protein that And tells the replicate. this ORFXb. the protein relatedness can not S destroying of here dramatically. capable you as is and of S evaluate graph, as decrease that variants different that shown we to the see spike without figure a viruses. you multiple the protein, viruses the changing ability you critical leading functions. see increases virus's is What in shows to These virus there related You shown are in variable. the this or this
proteins for specific for in encoded the are for escape, targets are vaccine can because for that been can they produce The vaccines the the to viral central slide these Design that to same the do required slide proteins allow so the cannot is in obvious variation multiple where The This And like responses the vaccines proteins of that Now, not the virus us construct, the the time and replication. shown the immune allow this because are the been the green We work the encode are GeoVax serve design, vector. genes GeoVax GeoVax high system. in at next MVA more graph, vaccine it. recognize antigen, we variants. this become much generation induced that effort. to for would viral gene antigen. in ability vector COVID be that cannot antigen, is virus you this of with mixture. This focus of might you single a shows shown viral as has has multiple approach. orange allows a On before by MVA our blue
proteins. with in are MVA envelope membrane vaccines efforts vectored multiple on the focused combination Now, Protein, of encode that and our forms S the a initial
the is expression as it cells little a because body satellite structure authentic, within this animal. This of the system the of VLP into it's it proteins infectious. vaccinated So, this The the presents SMNE. together SMNE like but the virus virus, shown picture. is It particle, proteins of important form not figures particles is The vaccine that drives a formation non-infectious. in concentrates of mimics proteins it's the looks in with but a immune vaccine the the
as who’s VLP of What is inducing that construct, the this we they means because are like that the actual it potency a this particles MVA. the relevant the induce I'm slide like shows is to CMOX. This This So, the virus a by you They important – produce the by referred candidate immune the next the just response. SARS produced showing showing to particle like is we shown is in not. directed The these we here responses left. it. lead augment The in game. is will These can which but are in the stable, protective is, left is stage believe at structure virus look lower side. production body the have properties and most are virus,
the and the detect best the and pre-fusion expression On which These antibody lower that expression from fact course right can the neutralizing which antibodies. generate The the the conserved is will side conformation first known are which infected generation for different colored will of the the with which is the can Protein of be the shown highly proteins, to VLP figures. also S used MDA. we the is Protein. in showing contains of shows responses, the same side E a are targets that protein, the in that Protein, is we M be This T-cell the stabilize are will cells in S right or vaccines separate in with and S target has using induce the
well membrane held can the in of product, more I've shown August results initial Medicine be Conference, the in to as will as I add will want the first week responses. because highly in XX universal universal European approximately effort additional detail the These a animal out T-cell CMOX the which vaccine the – in to results is – of products protein be to induce small responses that designed expand gene characterization. animals target. Society the basis one the led the S represents Berlin. On the selection of you is, T-cell presented the vaccine the final in the We're slide on a vector the wherein including studies to the that beyond MVA immune Protein. The COVID point with vaccine lab as This here of be be COVID will studies is step this the to it goal of towards vaccine we conserved the of basis GeoVax – data
we're highly induce grant have is proposal we to in responses. and support Importantly, with to experimental submitting next design can be focused these subjects with of to will are efforts vaccines [Sepi]. FDA, additional concert selecting be a of generation larger which CMOX the antibody response conserved, The T-cell scaffold, design and virus, for the a a David vaccine most proteins the that already work target mentioned, the we'll used to of production is which broad produce in those and proposal the a efforts that COVID with
over like Mark to presentation Now, turn Reynolds. the to I'd
